Fusion Pharmaceuticals (NASDAQ:FUSN – Get Free Report) had its target price decreased by equities research analysts at Raymond James from $13.00 to $12.00 in a report issued on Monday, MarketBeat.com reports. The brokerage presently has an “outperform” rating on the stock. Raymond James’ target price would suggest a potential upside of 277.36% from the stock’s […]
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Free Report) saw a significant drop in short interest in the month of July. As of July 31st, there was short interest totalling 101,200 shares, a drop of 17.3% from the July 15th total of 122,400 shares. Based on an average daily volume of 51,100 shares, the short-interest ratio […]
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Free Report) – Analysts at Wedbush boosted their Q3 2023 EPS estimates for Fusion Pharmaceuticals in a note issued to investors on Wednesday, August 9th. Wedbush analyst D. Nierengarten now anticipates that the company will earn ($0.38) per share for the quarter, up from their prior estimate of ($0.43). The […]
Virtu Financial LLC purchased a new position in Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Free Report) in the 1st quarter, HoldingsChannel.com reports. The fund purchased 13,084 shares of the company’s stock, valued at approximately $49,000. Several other institutional investors and hedge funds also recently added to or reduced their stakes in FUSN. Federated Hermes Inc. increased […]
Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Free Report) have earned an average recommendation of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have issued ratings on the stock […]